← Eichor
Study identifier: NCT06080880 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Ondanstron Weekly vs Every 3 Weeks for Prevention of Nausea and Vomiting Induced by Chemotherapy Combined With PD-1 Blockade

Condition: Nausea With Vomiting Chemotherapy-Induced  ·  Sponsor: Hubei Cancer Hospital

PhaseNA
Planned participants98
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The aim of this randomized study is to compare the efficacy and safety of ondanstron weekly with every 3 weeks for the prevention of nausea and vomiting induced by chemotherapy combined with PD-1 blockade.

This description comes directly from the study's public registry record.

Talk to the study team

Guang Han, MD  ·  13886048178  ·  hg7913@hotmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Hubei Cancer HospitalWuhan, Hubei, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06080880